Epstein Barr Virus News and Research

RSS
Epstein-Barr virus, frequently referred to as EBV, is a member of the herpesvirus family and one of the most common human viruses. The virus occurs worldwide, and most people become infected with EBV sometime during their lives. In the United States, as many as 95% of adults between 35 and 40 years of age have been infected. Infants become susceptible to EBV as soon as maternal antibody protection (present at birth) disappears. Many children become infected with EBV, and these infections usually cause no symptoms or are indistinguishable from the other mild, brief illnesses of childhood. In the United States and in other developed countries, many persons are not infected with EBV in their childhood years. When infection with EBV occurs during adolescence or young adulthood, it causes infectious mononucleosis 35% to 50% of the time.

Symptoms of infectious mononucleosis are fever, sore throat, and swollen lymph glands. Sometimes, a swollen spleen or liver involvement may develop. Heart problems or involvement of the central nervous system occurs only rarely, and infectious mononucleosis is almost never fatal. There are no known associations between active EBV infection and problems during pregnancy, such as miscarriages or birth defects. Although the symptoms of infectious mononucleosis usually resolve in 1 or 2 months, EBV remains dormant or latent in a few cells in the throat and blood for the rest of the person's life. Periodically, the virus can reactivate and is commonly found in the saliva of infected persons. This reactivation usually occurs without symptoms of illness.
Young patients with IBD have increased risk of severe viral infections

Young patients with IBD have increased risk of severe viral infections

New method to separate two variants of common herpes virus linked to multiple sclerosis

New method to separate two variants of common herpes virus linked to multiple sclerosis

Tailored T-cells safe, may be effective in preventing and treating multiple viral infections

Tailored T-cells safe, may be effective in preventing and treating multiple viral infections

Study uncovers new factor in the development of childhood lymphoma

Study uncovers new factor in the development of childhood lymphoma

Scientists reveal the structure of a key protein in Epstein-Barr virus infection

Scientists reveal the structure of a key protein in Epstein-Barr virus infection

Study sheds light on likely conserved functions of gammaherpesvirus microRNAs

Study sheds light on likely conserved functions of gammaherpesvirus microRNAs

Researchers identify encephalitis as rare toxicity of immunotherapy treatment

Researchers identify encephalitis as rare toxicity of immunotherapy treatment

How genetic differences in Epstein-Barr virus strains alter the way it behaves

How genetic differences in Epstein-Barr virus strains alter the way it behaves

PerkinElmer unveils CE-marked infectious disease immunoassays on EUROIMMUN random access instrument

PerkinElmer unveils CE-marked infectious disease immunoassays on EUROIMMUN random access instrument

Schizophrenia patients have higher levels of antibodies against Epstein-Barr virus, study shows

Schizophrenia patients have higher levels of antibodies against Epstein-Barr virus, study shows

ESMO Immuno-Oncology Congress showcases novel technologies set to benefit many cancer patients

ESMO Immuno-Oncology Congress showcases novel technologies set to benefit many cancer patients

Researchers discover possible path forward in preventing cancers tied to two viruses

Researchers discover possible path forward in preventing cancers tied to two viruses

Small populations of normal T cells could modify disease severity in patients with XLP1

Small populations of normal T cells could modify disease severity in patients with XLP1

Tick-borne disease is multiple microbial in nature

Tick-borne disease is multiple microbial in nature

FLX Bio treats first patient in its Phase 1/2 clinical trial of FLX475 for treating various advanced cancers

FLX Bio treats first patient in its Phase 1/2 clinical trial of FLX475 for treating various advanced cancers

Study provides complete picture of HPV virus-head and neck cancer connections

Study provides complete picture of HPV virus-head and neck cancer connections

Study could open new therapeutic avenues to attack herpesviruses

Study could open new therapeutic avenues to attack herpesviruses

Researchers find STAT3 as therapeutic target for chronic active EBV infection

Researchers find STAT3 as therapeutic target for chronic active EBV infection

New study finds key factors behind differences in immune responses

New study finds key factors behind differences in immune responses

Discovery of genes could lead to development of novel therapies for EBV-related cancers

Discovery of genes could lead to development of novel therapies for EBV-related cancers